Gilbert-Meulengracht’s syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?

References

• Adegoke, O. J., Shu, X. O., Gao, Y. T., Cai, Q., Breyer, J., Smith, J., et al. (2004). Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85:239–245.
   PubMed Web of Science ®Google Scholar
• Ando, Y., Chida, M., Nakayama, K., Saka, H., Kamataki, T. (1998a). The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8:357–360.
   PubMedGoogle Scholar
• Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., Kamataki, T. (1998b). UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845–847.
   PubMed Web of Science ®Google Scholar
• Aono, S., Adachi, Y., Uyama, E., Yamada, Y., Keino, H., Nanno, T., et al. (1995). Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert’s syndrome [see comments]. Lancet 345:958–959.
   PubMed Web of Science ®Google Scholar
• Aono, S., Yamada, Y., Keino, H., Hanada, N., Nakagawa, T., Sasaoka, Y., et al. (1993). Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-najjar syndrome type II. Biochem Biophys Res Commun 197:1239–1244.
   PubMed Web of Science ®Google Scholar
• Aono, S., Yamada, Y., Keino, H., Sasaoka, Y., Nakagawa, T., Onishi, S., et al. (1994). A new type of defect in the gene for bilirubin uridine 5’-diphosphate-glucuronosyltransferase in a patient with Crigler-najjar syndrome type I. Pediatr Res 35:629–632.
   PubMed Web of Science ®Google Scholar
• Arias, I. M. (1962). Chronic unconjugated hyperbilirubinemia without signs of overt hemolysis in adolescents and adults. J Clin Invest 41:2233–2245.
   PubMed Web of Science ®Google Scholar
• Balram, C., Sabapathy, K., Fei, G., Khoo, K. S., Lee, E. J. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12:81–83.
   PubMedGoogle Scholar
• Berk, P. D., Blaschke, T. F., Waggoner, J. G. (1972). Defective bromosulfophthalein clearance in patients with constitutional hepatic dysfunction (Gilbert’s syndrome). Gastroenterology 63:472–481.
   PubMed Web of Science ®Google Scholar
• Beutler, E., Gelbart, T., Demina, A. (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95:8170–8174.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., et al. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome [see comments]. NEJM 333:1171–1175.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Chowdhury, J. R., Huang, T. J., Lahiri, P., Elferink, R. P., Van Es, H. H., et al. (1992b). Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-najjar syndrome, type I. FASEB J 6:2859–2863.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Chowdhury, N. R., Goldhoorn, B. G., Hofker, M. H., Oude Elferink, R. P., Jansen, P. L., et al. (1992a). Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-najjar syndrome, type I. Hepatology 15:941–947.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Goldhoorn, B., Oude Elferink, R. P., Sinaasappel, M., Oostra, B. A., Jansen, P. L. (1993). A mutation in bilirubin uridine 5’-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-najjar syndrome type II [see comments]. Gastroenterology 105:216–220.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P., Chowdhury, J. R., et al. (1994). Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man [published erratum appears in J Biol Chem 1994;269:2542]. J Biol Chem 269:17960–17964.
   PubMed Web of Science ®Google Scholar
• Campbell, S. D., de Morais, S. M., Xu, J. J. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179–187.
   PubMed Web of Science ®Google Scholar
• Carlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., et al. (2005). UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226–1236.
   PubMed Web of Science ®Google Scholar
• Carulli, N., Ponz de Leon M., Mauro, E., Manenti, F., Ferrari, A. (1976). Alteration of drug metabolism in Gilbert’s syndrome. Gut 17:581–587.
   PubMed Web of Science ®Google Scholar
• Cecchin, E., Innocenti, F., D’Andrea, M., Corona, G., De Mattia, E., Biason, P., et al. (2009). Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457–2465.
   PubMed Web of Science ®Google Scholar
• Cheng, Z., Rios, G. R., King, C. D., Coffman, B. L., Green, M. D., Mojarrabi, B., et al. (1998). Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci 45:52–57.
   PubMed Web of Science ®Google Scholar
• Chouinard, S., Tessier, M., Vernouillet, G., Gauthier, S., Labrie, F., Barbier, O., et al. (2005). Inactivation of the pure antiestrogen Fulvestrant and other synthetic estrogen molecules by UGT1A enzymes expressed in the breast tissue. Mol Pharmacol Epub Dec 8.
   PubMed Web of Science ®Google Scholar
• Ciotti, M., Basu, N., Brangi, M., Owens, I. S. (1999). Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199–202.
   PubMed Web of Science ®Google Scholar
• Costa, E., Vieira, E., Martins, M., Saraiva, J., Cancela, E., Costa, M., et al. (2006). Analysis of the UDP-glucuronosyltransferase gene in Portuguese patients with a clinical diagnosis of Gilbert’s and Crigler-najjar syndromes. Blood Cells Mol Dis 36:91–97.
   PubMed Web of Science ®Google Scholar
• del Giudice, E. M., Perrotta, S., Nobili, B., Specchia, C., d’Urzo, G., Iolascon, A. (1999). Coinheritance of Gilbert’s syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 94:2259–2262.
   PubMed Web of Science ®Google Scholar
• Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre, randomised trial. Lancet 355:1041–1047.
   PubMed Web of Science ®Google Scholar
• Duguay, Y., McGrath, M., Lepine, J., Gagne, J. F., Hankinson, S. E., Colditz, G. A., et al. (2004). The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 64:1202–1207.
   PubMed Web of Science ®Google Scholar
• Ebner, T., Remmel, R. P., Burchell, B. (1993). Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 43:649–654.
   PubMed Web of Science ®Google Scholar
• Ehmer, U., Lankisch, T. O., Erichsen, T. J., Kalthoff, S., Freiberg, N., Wehmeier, M., et al. (2008). Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert’s syndrome marker, UGT1A1*28. J Mol Diagn 10:549–552.
   PubMed Web of Science ®Google Scholar
• Erps, L. T., Ritter, J. K., Hersh, J. H., Blossom, D., Martin, N. C., Owens, I. S. (1994). Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 93:564–570.
   PubMed Web of Science ®Google Scholar
• Fang, J. L., Beland, F. A., Doerge, D. R., Wiener, D., Guillemette, C., Marques, M. M., et al. (2002). Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978–1986.
   PubMed Web of Science ®Google Scholar
• Fang, J. L., Lazarus, P. (2004). Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomark Prev 13:102–109.
   PubMed Web of Science ®Google Scholar
• Farheen, S., Sengupta, S., Santra, A., Pal, S., Dhali, G. K., Chakravorty, M., et al. (2006). Gilbert’s syndrome: high frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene. World J Gastroenterol 12:2269–2275.
   PubMed Web of Science ®Google Scholar
• Folprecht, G., Kohne, C. H. (2004). The role of new agents in the treatment of colorectal cancer. Oncology 66:1–17.
   PubMed Web of Science ®Google Scholar
• Gagne, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., Guillemette, C. (2002). Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608–617.
   PubMed Web of Science ®Google Scholar
• Gajdos, V., Petit, F. M., Perret, C., Mollet-Boudjemline, A., Colin, P., Capel, L., et al. (2006). Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: The ECTIM Study. Clin Chem 52:2313–2314.
   PubMed Web of Science ®Google Scholar
• Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314–320.
   PubMed Web of Science ®Google Scholar
• Gilbert, A., Lereboullet, P. (1901). La cholamae simple familiale. [The simple hereditary cholestasis]. Sem Med 21:241–248.
   Google Scholar
• Guillemette, C., De Vivo, I., Hankinson, S. E., Haiman, C. A., Spiegelman, D., Housman, D. E., et al. (2001). Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomark Prev 10:711–714.
   PubMed Web of Science ®Google Scholar
• Guillemette, C., Millikan, R. C., Newman, B., Housman, D. E. (2000a). Genetic polymorphisms in uridine-diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950–956.
   PubMed Web of Science ®Google Scholar
• Guillemette, C., Ritter, J. K., Auyeung, D. J., Kessler, F. K., Housman, D. E. (2000b). Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene [in process citation]. Pharmacogenetics 10:629–644.
   PubMedGoogle Scholar
• Haverfield, E. V., McKenzie, C. A., Forrester, T., Bouzekri, N., Harding, R., Serjeant, G., et al. (2005). UGT1A1 variation and gallstone formation in sickle cell disease. Blood 105:968–972.
   PubMed Web of Science ®Google Scholar
• Innocenti, F., Grimsley, C., Das, S., Ramirez, J., Cheng, C., Kuttab-Boulos, H., et al. (2002). Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725–733.
   PubMedGoogle Scholar
• Innocenti, F., Ratain, M. J. (2003). Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park) 17(5 Suppl 5):52–55.
   PubMedGoogle Scholar
• Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., et al. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388. [Epub 2004 Mar 13].
   PubMed Web of Science ®Google Scholar
• Innocenti, F., Vokes, E. E., Ratain, M. J. (2006). Irinogenetics: what is the right star? J Clin Oncol 24:2221–2224.
   PubMed Web of Science ®Google Scholar
• Iyanagi, T. (1991). Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat). J Biol Chem 266:24048–24052.
   PubMed Web of Science ®Google Scholar
• Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., et al. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847–854.
   PubMed Web of Science ®Google Scholar
• Johnson, A. D., Kavousi, M., Smith, A. V., Chen, M. H., Dehghan, A., Aspelund, T., et al. (2009). Genomewide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 18:2700–2710.
   PubMed Web of Science ®Google Scholar
• Kapitulnik, J. (2004). Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 66:773–779.
   PubMed Web of Science ®Google Scholar
• Katoh, M., Yoshioka, Y., Nakagawa, N., Yokoi, T. (2009). Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. Drug Metab Pharmacokinet 24(3):226–234.
   PubMed Web of Science ®Google Scholar
• Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., Sato, K. (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191.
   PubMed Web of Science ®Google Scholar
• King, C. D., Green, M. D., Rios, G. R., Coffman, B. L., Owens, I. S., Bishop, W. P., et al. (1996). The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 332:92–100.
   PubMed Web of Science ®Google Scholar
• King, C. D., Rios, G. R., Green, M. D., MacKenzie, P. I., Tephly, T. R. (1997). Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 25:251–255.
   PubMed Web of Science ®Google Scholar
• Kohle, C., Mohrle, B., Munzel, P. A., Schwab, M., Wernet, D., Badary, O. A., et al. (2003). Frequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 65:1521–1527.
   PubMed Web of Science ®Google Scholar
• Kuehl, G. E., Lampe, J. W., Potter, J. D., Bigler, J. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027–1035.
   PubMed Web of Science ®Google Scholar
• Labrune, P., Myara, A., Hadchouel, M., Ronchi, F., Bernard, O., Trivin, F., et al. (1994). Genetic heterogeneity of Crigler-najjar syndrome type I: a study of 14 cases. Hum Genet 94:693–697.
   PubMed Web of Science ®Google Scholar
• Lampe, J. W., Bigler, J., Horner, N. K., Potter, J. D. (1999). UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9:341–349.
   PubMedGoogle Scholar
• Lankisch, T. O., Behrens, G., Ehmer, U., Mobius, U., Rockstroh, J., Wehmeier, M., et al. (2009). Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy—an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol 50:1010–1018.
   PubMed Web of Science ®Google Scholar
• Lankisch, T. O., Moebius, U., Wehmeier, M., Behrens, G., Manns, M. P., Schmidt, R. E., et al. (2006). Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44:1324–1332.
   PubMed Web of Science ®Google Scholar
• Lankisch, T. O., Schulz, C., Zwingers, T., Erichsen, T. J., Manns, M. P., Heinemann, V., et al. (2008). Gilbert’s syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomark Prev 17:695–701.
   PubMed Web of Science ®Google Scholar
• Lankisch, T. O., Vogel, A., Eilermann, S., Fiebeler, A., Krone, B., Barut, A., et al. (2005). Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67:1732–1739.
   PubMed Web of Science ®Google Scholar
• Lin, J. P., O’Donnell, C. J., Schwaiger, J. P., Cupples, L. A., Lingenhel, A., Hunt, S. C., et al. (2006). Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114:1476–1481.
   PubMed Web of Science ®Google Scholar
• Lin, J. P., Schwaiger, J. P., Cupples, L. A., O’Donnell, C. J., Zheng, G., Schoenborn, V., et al. (2009). Conditional linkage and genomewide association studies identify UGT1A1 as a major gene for antiatherogenic serum bilirubin levels—the Framingham Heart Study. Atherosclerosis Epub Mar 19.
   Web of Science ®Google Scholar
• Macklon, A. F., Savage, R. L., Rawlins, M. D. (1979). Gilbert’s syndrome and drug metabolism. Clin Pharmacokinet 4:223–232.
   PubMed Web of Science ®Google Scholar
• Maitland, M. L., Grimsley, C., Kuttab-Boulos, H., Witonsky, D., Kasza, K. E., Yang, L., et al. (2006). Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J 6:52–62.
   PubMed Web of Science ®Google Scholar
• Marcuello, E., Altes, A., Menoyo, A., Del Rio E., Gomez-Pardo, M., Baiget, M. (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678–682.
   PubMed Web of Science ®Google Scholar
• Martin, J. F., Vierling, J. M., Wolkoff, A. W., Scharschmidt, B. F., Vergalla, J., Waggoner, J. G., et al. (1976). Abnormal hepatic transport of indocyanine green in Gilbert’s syndrome. Gastroenterology 70:385–391.
   PubMed Web of Science ®Google Scholar
• McGrath, M., Lepine, J., Lee, I. M., Villeneuve, L., Buring, J., Guillemette, C., et al. (2009). Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genom 19:239–243.
   PubMed Web of Science ®Google Scholar
• Moghrabi, N., Clarke, D. J., Boxer, M., Burchell, B. (1993a). Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-najjar syndrome type 2. Genomics 18:171–173.
   PubMed Web of Science ®Google Scholar
• Moghrabi, N., Clarke, D. J., Burchell, B., Boxer, M. (1993b). Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar syndrome type I: implication in carrier detection and prenatal diagnosis. Am J Hum Genet 53:722–729.
   PubMed Web of Science ®Google Scholar
• Monaghan, G., Ryan, M., Seddon, R., Hume, R., Burchell, B. (1996). Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet 347:578–581.
   PubMed Web of Science ®Google Scholar
• Nguyen, N., Bonzo, J. A., Chen, S., Chouinard, S., Kelner, M. J., Hardiman, G., et al. (2008). Disruption of the UGT1 locus in mice resembles human Crigler-najjar type I disease. J Biol Chem 283:7901–7911.
   PubMed Web of Science ®Google Scholar
• Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., et al. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of cyp2c8: implications for drug-drug interactions. Drug Metab Dispos 34:191–197.
   PubMed Web of Science ®Google Scholar
• Onoue, M., Terada, T., Kobayashi, M., Katsura, T., Matsumoto, S., Yanagihara, K., et al. (2009). UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136–142.
   PubMed Web of Science ®Google Scholar
• Palomaki, G. E., Bradley, L. A., Douglas, M. P., Kolor, K., Dotson, W. D. (2009). Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11:21–34.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., et al. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505–512.
   PubMed Web of Science ®Google Scholar
• Rantner, B., Kollerits, B., Anderwald-Stadler, M., Klein-Weigel, P., Gruber, I., Gehringer, A., et al. (2008). Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 54:851–857.
   PubMed Web of Science ®Google Scholar
• Ribrag, V., Koscielny, S., Casasnovas, O., Cazeneuve, C., Brice, P., Morschhauser, F., et al. (2009). Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 113:3307–3313.
   PubMed Web of Science ®Google Scholar
• Rigato, I., Ostrow, J. D., Tiribelli, C. (2005). Bilirubin and the risk of common nonhepatic diseases. Trends Mol Med 11:277–283.
   PubMed Web of Science ®Google Scholar
• Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T., et al. (1992a). A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257–3261.
   PubMed Web of Science ®Google Scholar
• Ritter, J. K., Crawford, J. M., Owens, I. S. (1991). Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 266:1043–1047.
   PubMed Web of Science ®Google Scholar
• Ritter, J. K., Yeatman, M. T., Ferreira, P., Owens, I. S. (1992b). Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-najjar type I patient. J Clin Invest 90:150–155.
   PubMed Web of Science ®Google Scholar
• Ritter, J. K., Yeatman, M. T., Kaiser, C., Gridelli, B., Owens, I. S. (1993). A phenylalanine codon deletion at the UGT1 gene complex locus of a Crigler-najjar type I patient generates a pH-sensitive bilirubin UDP- glucuronosyltransferase. J Biol Chem 268:23573–23579.
   PubMed Web of Science ®Google Scholar
• Rotger, M., Taffe, P., Bleiber, G., Gunthard, H. F., Furrer, H., Vernazza, P., et al. (2005). Gilbert’s syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381–1386.
   PubMed Web of Science ®Google Scholar
• Rouits, E., Boisdron-Celle, M., Dumont, A., Guerin, O., Morel, A., Gamelin, E. (2004). Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151–5159.
   PubMed Web of Science ®Google Scholar
• Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H., et al. (2004). UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-;administered Japanese patients with cancer. Clin Pharmacol Ther 75:501–515.
   PubMed Web of Science ®Google Scholar
• Saracino, M. R., Bigler, J., Schwarz, Y., Chang, J. L., Li, S., Li, L., et al. (2009). Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1*28 polymorphism. J Nutr 139:555–560.
   PubMed Web of Science ®Google Scholar
• Schwertner, H. A., Vitek, L. (2008). Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198:1–11.
   PubMed Web of Science ®Google Scholar
• Seppen, J., Bosma, P. J., Goldhoorn, B. G., Bakker, C. T., Chowdhury, J. R., Chowdhury, N. R., et al. (1994). Discrimination between Crigler-najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 94:2385–2391.
   PubMed Web of Science ®Google Scholar
• Siow, R. C., Sato, H., Mann, G. E. (1999). Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: antiatherogenic actions of bilirubin and carbon monoxide? Cardiovasc Res 41:385–394.
   PubMed Web of Science ®Google Scholar
• Sparks, R., Ulrich, C. M., Bigler, J., Tworoger, S. S., Yasui, Y., Rajan, K. B., et al. (2004). UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6:R488–R498.
   PubMed Web of Science ®Google Scholar
• Stewart, C. F., Panetta, J. C., O’Shaughnessy, M. A., Throm, S. L., Fraga, C. H., Owens, T., et al. (2007). UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25:2594–2600.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P. (2008). Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics 9:903–915.
   Google Scholar
• Strassburg, C. P., Kalthoff, S., Ehmer, U. (2008). Variability and function of family 1 uridine-5’-diphosphate glucuronosyltransferases (UGT1A). Crit Rev Clin Lab Sci 45:485–530.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P., Manns, M. P. (2000). Jaundice, genes, and promoters. J Hepatol 33:476–479.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P., Vogel, A., Kneip, S., Tukey, R. H., Manns, M. P. (2002). Polymorphisms of the UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50:851–856.
   PubMed Web of Science ®Google Scholar
• Sugatani, J., Yamakawa, K., Yoshinari, K., Machida, T., Takagi, H., Mori, M., et al. (2002). Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292:492–497.
   PubMed Web of Science ®Google Scholar
• Sutomo, R., Laosombat, V., Sadewa, A. H., Yokoyama, N., Nakamura, H., Matsuo, M., et al. (2002). Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert’s syndrome. Pediatr Int 44:427–432.
   PubMed Web of Science ®Google Scholar
• Tallman, M. N., Miles, K., Kessler, F., Neilson, J., Tian, X., Ritter, J. K., et al. (2006). The contribution of intestinal UDP-glucuronosyltrasferases in modulating Sn-38 induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther Epub Sep 26.
   PubMed Web of Science ®Google Scholar
• Tang, K. S., Chiu, H. F., Chen, H. H., Eng, H. L., Tsai, C. J., Teng, H. C., et al. (2005). Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol 11:3250–3254.
   PubMed Web of Science ®Google Scholar
• Testa, R., Bardellini, E., Borzone, S., Montani, P., Risso, D., Bindi, P., et al. (1995). Caffeine clearance in subjects with constitutional unconjugated hyperbilirubinemia. Ital J Gastroenterol 27:129–132.
   PubMedGoogle Scholar
• Thomas, S. S., Li, S. S., Lampe, J. W., Potter, J. D., Bigler, J. (2006). Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27:717.
   PubMed Web of Science ®Google Scholar
• Tukey, R. H., Strassburg, C. P. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616.
   PubMed Web of Science ®Google Scholar
• Tukey, R. H., Strassburg, C. P., Mackenzie, P. I. (2002). Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446–450.
   PubMed Web of Science ®Google Scholar
• Udomuksorn, W., Elliot, D. J., Lewis, B. C., Mackenzie, P. I., Yoovathaworn, K., Miners, J. O. (2007). Influence of mutations associated with Gilbert’s and Crigler-najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genom 17:1017–1029.
   PubMed Web of Science ®Google Scholar
• Vasavda, N., Menzel, S., Kondaveeti, S., Maytham, E., Awogbade, M., Bannister, S., et al. (2007). The linear effects of alpha-;thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 138:263–270.
   PubMed Web of Science ®Google Scholar
• Vera, T., Granger, J. P., Stec, D. E. (2009). Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates angiotensin-II–dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol Epub Jul 1.
   Web of Science ®Google Scholar
• Wasmuth, H. E., Keppeler, H., Herrmann, U., Schirin-Sokhan, R., Barker, M., Lammert, F. (2006). Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis. Hepatology 43:738–741.
   PubMed Web of Science ®Google Scholar
• Zhang, D., Chando, T. J., Everett, D. W., Patten, C. J., Dehal, S. S., Humphreys, W. G. (2005). In vitro inhibition of UDP-glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729–1739.
   PubMed Web of Science ®Google Scholar
• Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 98:12671–12676.
   PubMed Web of Science ®Google Scholar